A retrospective multicenter study published in BMC Pediatrics provides new data on the clinical trajectory of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome. The research, conducted by the Turkish Society of Pediatric Hematology, analyzed records from 51 patients across 17 centers in Türkiye. The study highlights the significant long-term risks associated with this self-limiting clonal myeloproliferative disorder, particularly the subsequent development of Down syndrome-related myeloid leukemia (DS-ML) and early mortality.
TAM is a condition that affects approximately 5% to 30% of newborns with Down syndrome. While the disorder typically resolves without specific treatment in the majority of cases, it carries serious complications. The study notes that 10% to 23% of affected infants experience early death due to TAM-related issues, and 19% to 30% go on to develop DS-ML within the first few years of life.
In this cohort of 51 patients, the early mortality rate attributable specifically to TAM-related complications was 10%, with five patients dying within six months of diagnosis. An additional 10% of the cohort, also five patients, died from causes unrelated to TAM during the same period. The remaining patients who survived the initial critical period were monitored for the development of leukemia. The study found that complete clinical and hematological resolution of TAM was observed in 38 patients, representing 75% of the total group.
Among the 41 patients who survived the early postnatal period, 13 developed DS-ML. This corresponds to 32% of the survivors and 26% of the entire original cohort. The development of DS-ML in these patients underscores the persistent risk of malignancy even after the initial abnormal myelopoiesis has resolved. For the 13 patients who developed DS-ML, the estimated two-year overall survival rate was 84.6%, with a 95% confidence interval ranging from 51.2% to 95.9%. One patient in this subgroup died due to progressive disease, while two others died from infections.
When examining the entire cohort of 51 patients, the estimated three-year overall survival rate was 71.5%, with a 95% confidence interval of 55.4% to 82.6%. The three-year event-free survival rate was lower, at 47.4%, with a 95% confidence interval of 31.2% to 61.9%.
The study also conducted exploratory unadjusted competing-risk analyses to identify potential risk factors for early death. The analyses suggested differences in the six-month cumulative incidence of TAM-related death across several severe clinical and laboratory subgroups. However, the authors emphasize that these findings were based on only five TAM-related deaths and were not adjusted for multiple comparisons. Consequently, these subgroup analyses should be interpreted with caution and do not establish definitive causal links between specific clinical features and mortality risk.
The high rate of subsequent DS-ML development, particularly among survivors of the early neonatal period, reinforces the necessity for vigilant long-term follow-up. The study supports the clinical practice of monitoring these patients carefully for signs of leukemia, even after the initial TAM has completely resolved.
This research was published as an early view article, meaning it has been peer-reviewed and accepted but is subject to further edits before becoming the final version of record. The study does not involve clinical trials or the testing of new therapeutic interventions. Instead, it relies on retrospective data collection to describe natural history and outcomes.
Subject of Research: Clinical outcomes and leukemia risk in neonates with Down syndrome and transient abnormal myelopoiesis
Article Title: Transient abnormal myelopoiesis in down syndrome: Turkish society of pediatric hematology data
Article References: Düzenli Kar, Y., Ören, H., Zengin, E., Sarper, N., Çınar Özel, S., Kılınç Oktay, B., Güzelküçük, Z., Yaralı, N., Kaya, Z., Özdemir, Z. C., Aydın, S., Orhan, M. F., Eker, İ., Aral, Y. Z., Bahadır, A., Uzel, V. H., Akyay, A., Öncül, Y., Çakı Kılıç, S., … Meral GüneÅŸ, A. (2026). Transient abnormal myelopoiesis in down syndrome: Turkish society of pediatric hematology data. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07772-9
Image Credits: AI Generated
DOI: 10.1186/s12887-026-07772-9
Keywords: Down syndrome, Transient abnormal myelopoiesis, Pediatric hematology, Myeloid leukemia, Neonatal health, Clinical outcomes, Türkiye, Survival rates, Transient, abnormal, myelopoiesis, down
News Source: Harold Sullivan. (November 10, 2026). Turkish Study Tracks Leukemia Risk in Down Syndrome Infants. Scienmag.



